Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 1500 mg
fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1500 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 750 mg
fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
cefuroxim navamedic (cefuroxim villerton) stungulyfsstofn, lausn/dreifa 250 mg
navamedic asa - cefuroximum natríum - stungulyfsstofn, lausn/dreifa - 250 mg
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
ceprotin
takeda manufacturing austria ag - manna prótein c - purpura fulminans; protein c deficiency - blóðþurrðandi lyf - ceprotin is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
aprokam (cefcam) stungulyfsstofn, lausn 50 mg
laboratoires thea* - cefuroximum natríum - stungulyfsstofn, lausn - 50 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
zinacef stungulyfs-/innrennslisstofn, lausn 1,5 g
sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1,5 g
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
zinacef stungulyfs-/innrennslisstofn, lausn 750 mg
sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
lopid hart hylki 300 mg
pfizer aps - gemfibrozilum inn - hart hylki - 300 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
lopid filmuhúðuð tafla 600 mg
pfizer aps - gemfibrozilum inn - filmuhúðuð tafla - 600 mg
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - Æxlishemjandi lyf - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.